Scarica l'app Stockscreener
10.73
8.60%
0.85
Pre-mercato:
10.89
0.16
+1.49%
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus
Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks
Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener
Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.
Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks
California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush - Defense World
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com
Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks
Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
Intellia commercial position in question after safety event. says Goldman - TipRanks
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):